D.D. MUKHAMETOVA¹, D.I. ABDULGANIEVA¹, O.D. ZINKEVICH², N.A. SAPHINA², A.C. ODINTSOVA³

¹Kazan State Medical University

²Kazan State Medical Academy

³Republican Clinical Hospital

The article presents the results of a study of immune response to antigens of the intestinal microbiota in patients with inflammatory bowel disease. The study included 55 patients with flare of inflammatory bowel disease and 15 people in the control group. In patients with ulcerative colitis and Crohn’s disease were revealed specific reduction of Ig A, Ig M and rising of Ig G to most studied antigens in comparison with the control group. These changes correlated with duration of disease, endoscopic activity, clinical features and disease severity.

Key words: intestinal microbiota, immune response, Crohn’s disease, ulcerative colitis, inflammatory bowel diseases.

REFERENCES

1. Tkachev A.V., Mkrtchyan L.S., Nikitina K.E. et al. Inflammatory bowel disease: at the crossroads of problems. Prakticheskaya meditsina. Gastroenterologiya, 2012, no. 3 (12) (in Russ.).

2. Sa’ad Y. Salim, Johan D. Söderholm. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflammatory Bowel Diseases, 2011, January, vol. 17, issue 1, pp. 362-381.

3. Abraham C., Medzhitov R. Interactions Between the Host Innate Immune System and Microbes in Inflammatory Bowel Disease. Gastroenterology, 2011, May, vol. 140, issue 6, pp. 1729-1737.

4. Wehkamp J., Antoni L., Ostaff M., Stange E.F. The Intestinal Barrier in Implications for Future Therapeutic Intervention. Falk Foundation e.V, 2013, pp. 36-37.

5. Porras M., Martín M.T., Yang P.C. et al. Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation. Inflamm Bowel Dis, 2006, September, vol. 12, no. 9, pp. 843-52.

6. Osadchaya O.I., Boyarskaya A.M. Enterosorption influence on the development of humoral immunity reactions in patients with ulcerative colitis. Gazeta “Novosti meditsiny i farmatsii”. Meditsina segodnya, 2011, no, 11-12, pp. 371-372 (in Russ.).

7. Bulatov V.P., Kamalova A.A., Zinkevich O.D., Safina N.A. Role of systemic endotoxemia, antiendotoxin and antibacterial immunity in the development of duodenal ulcer in children. Pediatriya, 2011, vol. 90, no. 2, pp. 19-23 (in Russ.).

8. Best W.R., Becktel J.M., Singleton J.W. Rederived values of the eight coefficients of the Crohn’s disease activity index (CDAI). Gastroenterology, 1979, vol. 77, pp. 843-846.

9. Lewis J.D., Chuai Sh., Nessel L. et al. Use of the Non-invasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis. Inflamm Bowel Dis, 2008, December, vol. 14, no. 12m pp. 1660-1666.

10. Brandtzaeg P., Carlsen H.S., Halstensen T.S. The B-cell system in inflammatory bowel disease. Advances in Experimental Medicine and Biology, 2006, vol. 579, pp. 149-167.

11. Maeda S., Ohno K., Uchida K., Nakashima K. et al. Decreased immunoglobulin A concentrations in feces, duodenum, and peripheral blood mononuclear cells of dogs with inflammatory bowel disease. Journal of Veterinary Internal Medicine, 2013 January/February, vol. 27, issue 1, pp. 47-55.

12. Anikhovskaya I.A. Vyyavlenie grupp riska, vybor taktiki obsledovaniya i otsenka effektivnosti lecheniya razlichnykh zabolevaniy po pokazatelyam antiendotoksinovogo immuniteta: avtoref. dis. … kand. med. nauk [Identification of risk groups, the choice of tactics examination and evaluation of the effectiveness of treatment of various diseases in terms antiendotoxin immunity. Synopsis of the dis. of the PhD med. sci]. Moscow, 2001. 18 p.

13. Champion K., Chiu L., Ferbas J., Pepe M. Endotoxin neutralization as a biomonitor for inflammatory bowel disease. PLoS One, 2013, June 24, vol. 8, no. 6, e67736.

14. Khamitov R.F., Latfullin I.A., Bogoyavlenskaya O.V. et al. Osnovy laboratornoy diagnostiki. Uchebno-metodicheskoe posobie dlya sistemy poslevuzovskogo professional’nogo obrazovaniya [Basics of laboratory diagnostics. Teaching aid for postgraduate education system]. Kazan, 2009. P. 67.

15. Philippe D., Heupel E., Blum-Sperisen S. et al. Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. International Journal of Food Microbiology, vol. 149, issue 1, 2011, September 1, pp. 45-49.